NCT07307040Not yet recruiting
Precision Diabetes Management: Integrated East-West Approach
Construction of a Precision and Individualized Management Model for Diabetes With Integrated Traditional Chinese and Western Medicine
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
This project will leverage a large-scale cohort of early-onset type 2 diabetes patients to conduct innovative prospective clinical research. By integrating traditional Chinese medicine diagnostic information, clinical data, laboratory results, continuous glucose monitoring, genetic information, multi-omics data, and multi-modal monitoring data, and utilizing advanced data analysis methods such as deep learning, the project aims to establish a comprehensive monitoring, precise classification, and personalized diagnosis and treatment model-a holistic management approach integrating traditional Chinese and Western medicine for early-onset type 2 diabetes. This initiative is expected to enhance the management of early-onset type 2 diabetes, improve treatment outcomes and quality of life for affected patients, pioneer an innovative path for personalized integrated traditional Chinese and Western medicine management in this population, and promote the application of precision medicine in diabetes prevention and treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 31 Dec 2025
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07307040
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 31 Dec 2025 to the primary completion date, 31 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The clinical diagnosis was type 1 diabetes, and at the time of enrollment, antibody levels or insulin/C-peptide results still supported the original diagnosis.
- There were clear secondary factors contributing to hyperglycemia, such as Cushing's syndrome or pheochromocytoma.
Who the study is looking for
- The age at diabetes diagnosis is ≥18 years but \<40 years.
Age in the registry: 18 years to 40 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.